Transversus Abdominis Plane Blocks With Ropivacaine Continuous Infusion Catheters versus Single Dose Liposomal Bupivacaine for Pain Control After Kidney Transplant Surgery

What this Trial Is About

This research aims to compare the pain relief effectiveness of two types of transversus abdominis plane (TAP) blocks in adults undergoing kidney transplant surgery. Specifically, it evaluates continuous ropivacaine infusion via catheters against a single dose of liposomal bupivacaine, both administered under ultrasound guidance. The study is a prospective randomized control trial conducted to better understand pain management after renal transplant operations. Participants are divided into two groups. One group receives a TAP block with a ropivacaine bolus followed by continuous infusion through a catheter placed into the TAP space, with dosing initiated at 8 ml per hour of 0.2% ropivacaine on the inpatient floor. The other group receives a single-shot TAP block using liposomal bupivacaine diluted with preservative-free saline and injected into the TAP area after initial skin infiltration with plain bupivacaine. During the study, participants' total opioid use will be measured for four days after surgery to assess pain control. Other assessments include pain scores indicating severe pain, postoperative nausea and vomiting, respiratory depression, length of hospital stay, and costs related to analgesia up to two weeks post-surgery. The trial includes close monitoring of pain and side effects, with all procedures performed under medical supervision to evaluate the analgesic effects of the interventions.

TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant